In the case of ovarian cancer, for instance, the research conducted by Gomez and colleagues highlighted a beneficial strategy to reverse immune escape through the combination of DNA methyltransferase inhibitors (DNMTis) with ADAR1 inhibition (236). Here, ADAR is linked to ovarian carcinoma.